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Background: Epidemiological studies describe a latitude gradient for increased MS prevalence and a preponderance
of disease in Caucasian individuals. However, individuals from other ethnic backgrounds and low-risk regions can
acquire a raised risk through migration. Nearly a fifth of the London population is of Asian/Asian-British origin and a
significant proportion of referrals are from this group.
Methods: We investigated whether there were differences in timing, presentation, severity, and immunology of
disease (with respect to CD4 myelin epitope recognition) between individuals in London with MS who were either of
S. Asian or Caucasian origin. Individuals of S. Asian origin with MS were compared with healthy S. Asian controls,
individuals with MS and of Caucasian origin and Caucasian controls.
Results: Age at MS onset is significantly lower in the S. Asian group, attributable to earlier onset specifically in UK-born
individuals, though clinical presentation is similar. Analysis of CD4 autoimmunity to myelin antigens shows disease in S.
Asian individuals to encompass recognition of novel epitopes; immunity to MBP116-130 in S. Asian individuals was
highly disease-specific.
Conclusions: These findings emphasize the need to define disease profiles across ethnicities and identify
environmental triggers conferring acquired risk. Such findings must inform choices for immunotherapeutic
interventions suitable for all, across ethnicities.
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MS is a chronic, immune-mediated, inflammatory disease
of the CNS, a widely held view of disease aetiology being
that CD4 and CD8 T cells specific for myelin epitopes, ac-
tivated as a result of immune dysregulation in genetically
predisposed individuals, migrate across the blood–brain
barrier. Once in the CNS, they initiate an inflammatory
cascade leading to myelin destruction and axonal loss [1].
Commonly studied myelin antigens are myelin basic
protein (MBP), proteolipid protein (PLP) and myelin
oligodendrocyte glycoprotein (MOG), though diverse
CNS proteins may be targeted [2].
Twin studies show that genetic factors determine
around one third of MS risk, the remaining risk arising* Correspondence: d.altmann@ic.ac.uk
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unless otherwise stated.from the environment [3,4]. The genetic component of
risk is complex and multigenic, encompassing a prepon-
derance of immune system genes [4-7].
In S. Asians in India, Pakistan, Bangladesh and Sri
Lanka, the prevalence of MS is low, around 3/100,000
[8-10], an exception being the Bombay and Poona Zoro-
astrian community, where it is 40/100,000 [11]. Clinical
presentation in S. Asians shares characteristics with the
‘Western’ type of MS [12] in contrast to the ‘optic-spinal’
pattern observed in SE Asia [13]. From analysis to date,
MS-associated loci are likely to be similar between
Indian and European individuals with MS [14]. With a
disease as heterogeneous in presentation as MS, the fact
that environmental origins and genetic background may
play a part in presentation makes it desirable, both for
an understanding of aetiology and for the delivery of
appropriately tailored care, that disease is characterized
in different ethnic and geographic contexts.l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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by the finding that risk varies in immigrants with country
of residence and duration of residence in the new country.
Environmental factors considered to contribute to this risk
include ultraviolet light, vitamin D, diet, parasite burden,
EBV seropositivity and immunization [15,16]. Enhanced
risk is crystallized in populations migrating from a low to
a high-prevalence area, as shown in the 1990s in UK and
French immigrants from India, Africa and the West
Indies [17,18]. MS in African-Americans has been
well-documented, showing a more oculo-spinal pattern
and more aggressive disease, with a smaller role for
HLA susceptibility genes, although including effects of
HLA-DR15 and HLA-DR3 alleles [19,20].
The rising prevalence in UK S. Asians [17] led us to
investigate whether clinical presentation and autoimmun-




Ethical approval was obtained from the Thames Valley
Multicentre Ethics Committee (05/MRE12/8). Clinical
data included: age, sex, disease onset, family history, clin-
ical course, clinical status, first and present symptoms and
signs, treatment and Extended Disability Severity Scores
(EDSS); using this data the MS severity score (MSSS) was
calculated [21] (Table 1). Diagnosis was based on McDo-
nald criteria [22]. Patients of S. Asian origin were asked
ethnicity, place of birth, age of immigration to UK, previ-
ous country of residence and grandparents’ language;
patients confirmed that both parental origins were from
S. Asia. Caucasian individuals with MS were recruited
through the same clinic. S. Asian controls were unrelatedTable 1 Comparative demographic characteristics of the
South Asian and Caucasian subjects
South Asian MS Caucasian MS
N 30 34
Age at study (mean ± SD) 33.9 ± 10.9 40.79 ± 10.0*
Male:female 7:23 11:23
Ethnicity Indian:Pakistani origin 23:7 -
Immigrated <14 yrs, UK Born: >14 24:6 -
MS type RR/SP/CIS 28/2/0 29/3/2
Family history of MS 5 3
Age of onset (mean ± SD) 27.7 ± 8.6 32.7 ± 9.2**
Length of disease at time of study 8.3 ± 7.0 9.7 ± 8.5
Treatment
MSSS 5.5 ± 2.8 4.6 ± 3.1
Relapses in first 3 years 2.8 ± 2.1 2.6 ± 2.0
Demographic comparison of studied populations.
(*p < 0.003, **p < 0.03).to the individuals with MS, and Caucasians controls were
recruited from laboratory staff with informed consent. To
summarise, the recruitment criterion for inclusion in this
study was that subjects were recruited for this study se-
quentially from those patients attending clinic who had
clinically definite MS, who agreed to participate and who
were of South Asian or Caucasian origin.
IFNγ ELISpot assay for myelin CD4 epitopes
PBMCs isolated over Histopaque (Sigma-Aldrich, UK)
and resuspended in AIM V (Gibco, Invitrogen, UK) serum
free medium (350,000 cells/50 μl), were stimulated with
15-mer peptides (Genscript) spanning the MBP and MOG
sequences with 5 amino acid overlaps, including 4 b2 iso-
forms for MOG 157–171, 162–176, 167–181, 172–186 at
a final peptide concentration of 10 μg/ml. Pools of 6
peptides in triplicate were utilised, each peptide in two
pools: To give us coverage of what are relatively large
myelin peptide panels with which to screen CD4 T cell
responses using a relatively limited peripheral blood
sample, we used the well-established approach of com-
bining peptides into cocktails of 6 peptides and tested in
triplicate, as has previously been described [23]. This
approach yielded 30 cocktails, each individual peptide
present in two separate groups with 5 other peptides.
The 5 other peptides were either from the other mol-
ecule tested (MBP or MOG) and from separate areas of
the same molecule. To have a positive response the pep-
tide had to fulfil the response criteria in both groups
that the peptide was present in thus increasing the
certainty of a positive response. PBMC responses to
peptide were assessed by IFNγ ELISpot. Polyvinylidene
fluoride-coated microplates (Millipore, UK) were over-
night (4 °C) with capture antibody (Diaclone, France)
1:100 in PBS. After washing, plates were incubated with
2% skimmed dry milk (Diaclone, France) in PBS for 2 h
(room temperature). PBMC were added at 350,000/well.
Positive control wells received M. Tuberculosis puri-
fied protein derivative (PPD, Statens Serum Institute,
Denmark) 1:100 in 50 μl medium. Peptide pools in
50 μl medium were added to wells and plates incubated
for 36 h. They were emptied and incubated with PBS/
0.1% tween 20 for 10 min, washed with PBS/0.1%
tween 20 and incubated (90 min) in detection anti-
body (1:100 in PBS/1% BSA). After washing, 1:1000
streptavidin-alkaline phosphatase in PBS/1% BSA was
added for 90 minutes, plates then washed and incu-
bated for 5 minutes in BCIP/NBT buffer. Spots were
read on an AID ELISpot Reader and results expressed
as mean number of spots/106 cells. A positive response
was called based on being >mean from 6 medium control
wells +2SD. Assays on donor PBMC without a significant
positive control response to PPD were excluded from fur-
ther analysis.
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HLA genotypes of genomic DNA samples were deter-
mined at the Tissue Typing facility at Hammersmith
Hospital NHS Trust as previously described [24].Statistical analysis
The sum of positive CD4 T cell responses was com-
pared between S. Asian and Caucasian controls and
individuals with MS. Chi squared/Fisher test were
used to identify significant differences for each CD4 T
cell epitope. Multivariate analysis was carried out
using the co-variates sex, age, disease status and ethni-
city using R.Results
Ethnicity and demographics
Thirty S. Asian subjects with McDonald MS were stud-
ied of whom twenty-three were of Indian origin and
seven, Pakistani. Four of the S. Asian patients were
born in Africa. Twenty-four S. Asians with MS immi-
grated to the UK under the age of 14 or were born in
UK (− 17 were UK-born). Six immigrated to the UK
above the age 0f 14. All had relapsing/remitting MS
(RRMS). Twenty-one S. Asian controls, of which fif-
teen were included in the immunological analysis, had
a mean age of 34.52 ± 10.46 years. Twenty were Indian
and one was Pakistani. There were no significant dif-
ferences between the S. Asian control and MS popula-
tion. Thirty-four Caucasian subjects with MS were
studied (29 included in T cell analysis) and 25 Cauca-
sian controls (22 included for T cell analysis). There
was no difference between the Caucasian control and
MS groups but in those with MS the Caucasians were
significantly older than the S. Asians with MS (Table 1).
A larger study will be required to determine whether
there are HLA class I or class II associations specific-
ally associated with disease risk in this population: in
this relatively small sample, there is a possible effect on
disease risk of HLA-DR3, but this does not reach sig-
nificance (Additional file 1: Table S1).Figure 1 MBP and MOG CD4 T cells responses are correlated but for
each of the MBP and MOG proteins Caucasian donors with MS
respond to fewer epitopes.MS onset occurs at a younger age in UK-born S. Asians
The mean age of MS onset is lower in the S. Asian group
than in the Caucasian (Table 1; 27.7 ± 8.6, 32.7 ± 9.2, t-
test, p < 0.03). Thus, though the S. Asian group was
studied at a younger age than the Caucasian group
with MS, there was no difference between the times for
which they had had MS (3.3 ± 7.0, 9.7 ± 8.5, NS). The
lower age of MS onset in S. Asians is a result of the low
age of onset in UK-born South Asians compared to
non-UK-born S. Asians (n = 17, 22.9 ± 6.3 years, n = 13,
33.8 ± 7.1 years, t-test, p < 0.0003).Clinical presentation, course and use of disease modifying
drugs is similar in S. Asians and Caucasians
There was no difference between the MSSS or relapses
in the first 3y between UK- and non-UK-born S. Asians
(Table 1). Optic neuritis was the first symptom in 15% of
S. Asian patients (bilateral in one of them) and 31% of
Caucasians (bilateral in one) but it later affected 37% of
S. Asian patients and 35% of Caucasians. There was no
significant difference in first symptoms between S.
Asians (UK or non-UK born) and Caucasians (Fishers
test/x2). At the time of assessment, the dominant symp-
toms in S. Asian individuals were motor in 64% and
cerebellar in 54%. In the Caucasian group, the dominant
symptoms were motor in 48% and cerebellar in 41%.
There was no significant difference between current
symptoms found between S. Asians (UK or non-UK
born) and Caucasians.
There was no difference between the use of treatments
in S. Asians and Caucasians. Thirty two per cent and
41% of S. Asians and Caucasians respectively were on
therapy for at least 3 months prior to sample collection.
Treatments included beta-interferon, glatiramer acetate
and Natalizumab and were equally distributed between
S. Asians and Caucasians.
MBP and MOG reactivity is correlated within subject but
disease in S. Asians involves broader epitope responses
We studied CD4 T cell autoreactivity to myelin epitopes
in S. Asian and Caucasian subjects. We observed a
strong correlation between a response to MBP and a re-
sponse to MOG (Figure 1, n = 94, r = 0.88, p < 0.0001): if
a subject showed CD4 immunity to a high number of
MBP responses, they were likely to show a high number
of MOG responses. Multivariate analysis was performed
for the variables, MBP and MOG epitope recognition,
Figure 2 South Asian MS patients show a broader myelin T cell
response. Compared to Caucasians with MS (A and B, column 1)
there were increased numbers of recognized T cell epitopes in UK
born South Asians (A and B, column 2) for both MBP (A, *p = 0.009)
and MOG (B, **p = 0.017). In non-UK born South Asians, there was
an increase in the number of recognized T cell epitopes in those
with a disease onset greater than or equal to 30 years (A and B,
column 4) compared to those with a disease onset under the age
of 30 years (A and B, column 3). This was significant for both MBP
(A, **p = 0.036) and MOG (B, ****p = 0.015).
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MS) and ethnicity, together with an interaction between
ethnicity and disease status. Increased numbers of MBP
epitopes were associated (R2 0.14, p < 0.01) with in-
creased age (estimate = 0.2, p = 0.086) and reduced
numbers were associated with being Caucasian and
having MS (estimate = −8.2, p = 0.07). Similarly increased
numbers of MOG epitopes were associated (R2 0.14, p <
0.009) with increased age (estimate = 0.3, p < 0.0175) and
reduced numbers were associated with being Caucasian
and having MS (estimate = −9.3, p = 0.071).
UK born S. Asians with MS and non-UK born S. Asians
with disease onset at or over age 30y show CD4
responses to more MBP and MOG epitopes
Multivariate analysis confirmed that MBP and MOG re-
activity was not associated with earlier disease-onset,
length of disease, high early relapse rates or EDSS at
time of assessment. We found a significant difference
between the numbers of CD4 epitopes for both MBP
(Figure 2A) and MOG (Figure 2B) between Caucasians
and S. Asians, UK born or who immigrated before the
age of 14 years. The rise in CD4 myelin autoreactivity
was also seen in non-UK born S. Asians who had disease
onset greater than or equal to 30 years of age compared
to those who had a disease onset less than 30 years
(Figure 2A and B). This implies that myelin T cell auto-
reactivity may increase in relation to time of UK envir-
onmental exposure and not with MS per se or its onset.
Mapping of disease-related myelin epitope recognition in
Caucasian and S. Asian MS patients
It has been established through T cell studies over many
decades that myelin autoreactivity per se is not a correl-
ate of disease, since responses to myelin antigens can be
elicited by culture of PBMC from most healthy controls
[25]. However, some T cell epitopes have been docu-
mented in terms of immunodominance in disease or
temporal association with relapse [26-28]. We therefore
analyzed comparative responses to MBP and MOG be-
tween S. Asian and Caucasian subjects and matched
controls (Figure 3A-D). We observed different prefer-
ences for disease-related myelin T cell epitopes between
the ethnicities. We did not observe global differences in
T cell immunity between the groups in assays against
other antigens such as PPD.
Myelin autoreactivity appeared against a background
of greater myelin immunity in all S. Asian donors, in-
cluding controls: many MOG and MBP epitopes elicited
a response from PBMC of a minority of S. Asian con-
trols. However, a small number of epitopes were more
commonly detected in the responses of PBMC from S.
Asian MS than control donors, notably MBP116-130
(Figure 3A). The 116–130 epitope was recognized by Tcells from a third of MS patients but no controls. Inter-
estingly, this epitope is part of a myelin peptide cocktail
currently in clinical trial for immune modulation of
disease [29] and is described in Japanese MS patients
with optico-spinal disease [30]. Autoreactivity to MBP in
Caucasian patients was different, with many epitopes
more frequently recognized by controls than in patients,
but with a focus of immune recognition in patients for
the epitopes MOG 101–115 and MOG 111–125
(Figure 3C). In Caucasian donors, a response to
MBP116-30 is seen but does not differ in frequency be-
tween patients and controls (Figure 3C). The focus of
immune reactivity in response to MOG also differed
between cohorts, CD4 responses to MOG −2-13, 149–163
Figure 3 Frequency of T cell response to specific MBP and MOG epitopes in South Asian and Caucasian subjects. The frequency of CD4 T cell
responses to the peptide panels was evaluated with respect to MBP recognition for South Asian controls (black columns) compared to South
Asian MS subjects (white columns) (A), MOG recognition for South Asian controls (black columns) compared to South Asian MS subjects (white
columns) (B), MBP recognition for Caucasian controls (black columns) compared to Caucasian MS subjects (white columns) (C), and MOG
recognition for Caucasian controls (black columns) compared to Caucasian MS subjects (white columns) (D). As described in the Methods,
epitope responses were derived from decoding responses to individual peptides from ELIspot spot-forming cell (SFC) frequencies observed in
response to pooled peptide cocktails. A. South Asian MS subjects responded more commonly than South Asian controls to several MBP epitopes,
notably MBP116-130 – a response only observed in individuals with MS (**p < 0.02). Comparison with respect to recognition of the MOG peptide
panel is shown in (B). South Asian individuals with MS responded significantly more frequently than South Asian controls to epitopes within
MOG-2-13, MOG149-163 MOG204-228 (***p < 0.01) and MOG174-188 (*p < 0.05). The frequency of CD4 T cell responses to the peptide panels was
evaluated with respect to MBP recognition for Caucasian controls (black columns) compared to Caucasian MS subjects (white columns) is shown
in (C) and for the MOG panel (D). For a number of MBP epitopes, T cell recognition by Caucasian MS subjects was actually less common than
recognition by T cells of Caucasian controls, highly significantly at MBP16-30, MBP151-165 and MBP156-170 (***p < 0.01) and significantly at
MBP21-35, MBP31-45, MBP36-50, MBP46-60, MBP56-70, MBP86-100, MBP171-185 (* < 0.05). Only for MBP101-115 and MBP111-125 (^<0.05, on one
sided Chi-Squared) was there an increase in frequency of responses in MS Caucasian MS patients compared to controls. Frequency of MOG
epitope recognition in Caucasian MS subjects showed more frequent responses by controls than MS patients to MOG109-123, MOG129-143,
MOG184-198 (***p<0.01) and to MOG4-18, MOG39-53, MOG154-168, MOG204-228 (*p<0.05) The response to MOG64-78 was more frequent in
Caucasian MS patients than controls (^ p<0.01) and the response to MOG209-233 showed a marginally significant increase in susceptibility
( ^ <0.05, on one sided Chi-Squared).
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cohort (Figure 3B) while responses to MOG 64–78 and
209–233 are more disease-specific in the Caucasian co-
hort (Figure 3D).
CD4 T cell responses of HLA DR15+ S. Asians and
Caucasians with MS focus on different disease-specific
MBP and MOG epitopes
HLA-DR15 was more common in the Caucasians with
MS (44.4%) than in their respective controls (17.6%),
though this did not reach significance (X2 test, p = 0.06).
There was a slight over-representation of HLA-DR15 inthe S. Asian individuals, 27% of patients and 19% of con-
trols (Additional file 1: Table S1). A potential explan-
ation for differential patterns of T cell reactivity between
donors of differing ethnicity would be differences in the
frequency of the HLA class II alleles involved in self-
peptide presentation. We addressed this by comparing
disease cohorts for myelin epitope recognition, filtering
just for those donors who are DR15/DRx (Figure 4). This
demonstrates that, even filtered for HLA-DR15 carriage,
myelin T cell responses are dissimilar between Asian
and Caucasian cohorts, with reactivity to MBP being
more common overall, but only significantly so with
Figure 4 Comparative MBP CD4 T cell responses in the example of HLA-DR15CP South Asian and Caucasian MS subjects. Frequencies of CD4 T
cell response to MBP (A) in HLA-DR15+ individuals with MS who are of South Asian origin (black columns) or of Caucasian origin CSouth Asian
MS subjects, reactivity to MBP was more common but was only significantly more frequent than in Caucasian MS subjects for MBP141-155
(*p<0.05). Frequencies of response to MOG epitopes are indicated in the lower panel (B). Responses in South Asian MS subjects were not
significantly different to the responses in Caucasian MS.
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T cell response was not seen in DR15+ Caucasian individ-
uals with MS. DR15+ S. Asians with MS tended to show
positive T cell responses to a larger number of MOG Tcell
epitopes than Caucasian donors with MS, though this
difference did not reach statistical significance withrespect to differential responses to any specific epi-
topes (Figure 4B). Multivariate analysis for age at on-
set, CD4 epitopes and presence of MS found a
significant model (R2 0.133, p = 0.023) with two vari-
ates, recognition of MOG64-78 (6.0, p = 0.035) and
MOG174-188 (−6.9, p = 0.01) - a subject being negative
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188 resulted in a lower age of MS onset, irrespective of
ethnicity.
Discussion
It is a given in MS aetiology research that a key to
unlocking the mysteries of the interplay between genetics
and environment in this disease is the acquired disease risk
of migrating populations. Individuals from the South Asian
sub-continent who have migrated to the UK acquire an MS
risk elevated by some 30-40-fold. As an MS referral clinic
based in an area of W. London with a sizeable community
originating from S. Asia, we see a substantial number of pa-
tients from this group. We show that disease profile is simi-
lar to that seen in individuals of European origin, except
that disease in the S. Asian group disease is of significantly
earlier onset, attributable to earlier onset in UK-born com-
pared to non-UK-born S. Asians. Is it possible, however,
that a lack of late-onset MS seen in South Asian patients
may reflect a skewing in the age-distribution in the South
Asian community? Reference to U.K. demographic data
relative to self-declared ethnicity (see for example https://
docs.google.com/spreadsheet/ccc?key=0AonYZs4MzlZbdF
J6OVF1U3JZTXEyYnFjb0k1clJvOFE&hl=en#gid=0) indi-
cates that there is indeed a relatively smaller pool of
elderly South Asians in the UK community in whom
we could have picked up later onset disease, the UK
Asian population being somewhat more skewed to in-
dividuals under the age of 50 than the UK Caucasian
population. However, note that our data relate simply
to reported age at first diagnosis.
This study is the first to localize this disease feature to
a population coming from a low risk area to a high-risk
area, implying it also has an environmental basis. We
demonstrate that a combination of MOG reactivity is as-
sociated with early disease onset that is not associated
with ethnicity. This will require further validation in lar-
ger cohorts, but argues that the environmental triggers
impacting on the kinetics of MS onset are likely to be
ones that operate primarily in early life. Hypotheses as
to the nature of these differential triggers have tended to
encompass cross-reactivities/molecular mimicry between
myelin antigens and common pathogens, more general
notions of immune dysregulation in relation to hygiene-
related cytokine deviation and/or climate differences in-
cluding UV-D exposure. In light of recent structural
studies by Birnbaum and colleagues, this list should be
broadened to encompass immune cross-reactivity be-
tween myelin epitopes and the environmental exposo-
some [31].
The comparative clinical picture and immunogenetics
of MS in African-Americans has been fairly extensively
studied and has been useful in teasing out aspects of dis-
ease aetiology and variation. HLA genes confer raisedsusceptibility to MS in African Americans, although to a
smaller degree than in individuals of European descent
[32]. The lesser degree of linkage disequilibrium (LD) in
HLA regions of African Americans has been valuable in
dissecting the relative disease contributions of loci in
this region, placing greater emphasis on DRB1 polymor-
phisms than on DRB5, DQB1 or class I genes. The rela-
tively small cohort of Asian patients studied here showed
an excess of individuals carrying a ‘DR3-DQ2’ auto-
immunity haplotype, as reported in African-American MS
studies.
The present study is the first to compare CD4 epitope
reactivity of myelin antigens between Caucasians and
South Asians, potentially illuminating understanding of
disease-related immune responses. While immunodomi-
nant epitopes from the myelin sheath have been impli-
cated in MS, the breadth of the immune response and
the fact that immunity is studied once disease has been
active for a prolonged period makes for the attribution
of specific pathogenic response patterns difficult
[1,3,25-28,33]. We previously evaluated ‘epitope spread’
during the time-course of MS - the notion that the CD4 T
cell response broadens with time and is thus implicated in
CNS immunopathogenesis [34]. Our new findings impose
a caveat on this model: ethnic differences in myelin auto-
reactivity may dominate over any relationship to specific
disease duration or severity. Some MBP T cell responses
were found more commonly in S. Asian MS patients than
in Caucasian MS patients, notably MBP116-130. This was
in contrast to T cell responses in Caucasian patients,
which focused on MBP 16–30, 151–165 and 156–170.
MBP 116–130 was highlighted in a study of T cell reactiv-
ity in Japanese MS patients with optico-spinal disease
presentation [30]. As shown in Figure 4, even filtering on
those donors who were HLA-DR15+, the differences in
myelin T cell recognitions between Asian and Caucasian
individuals with MS was striking. There are several
possible explanations for these differing patterns of
self-recognition and more detailed studies will be re-
quired to illuminate them. GWAS studies indicate a
large number of immune-related disease loci contrib-
uting to MS risk and many of these differ between S.
Asians and Caucasians. Since several impact on fine-
tuning of adaptive immunity, from antigen processing
to regulation of HLA expression, accessory molecules
and cytokines, it is unsurprising to detect differences
in myelin autoimmunity. Alternatively, taking a view
that deregulation of the autoreactive repertoire results
from cross-reactive or pro-inflammatory immune stimula-
tion occurring through microbial stimulation or other
environmental antigens, then changed patterns of self-
reactivity may reflect different expososome histories.
Indeed, the more extensive myelin autoreactivity that we
observed in our S. Asian control cohort may suggest a
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differences, even in healthy individuals.
Conclusions
Whatever mechanisms underlie this differential immune
focus, the observations raise issues. Among immune
therapeutics currently in clinical trial or pre-clinical de-
velopment, a number depend upon variants of peptide
tolerance, based on a ‘one-size-fits-all’ best-guess of MS
epitopes [29,35,36]. The differences observed here in
clinical presentation and immunology, argue for a strati-
fied approach embracing these differences.
Additional file
Additional file 1: Table S1. HLA class II gene frequencies in South
Asians with MS and controls. Allele frequencies are given with respect to
the total number of haplotypes tested in each group, that is 30 individuals
(60 haplotypes) for the patients and 13 individuals (26 haplotypes) for the
controls.
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